3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
4
Completed
3
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
CNS
1
Conditions
Melanoma
4
Thyroid Carcinoma, Anaplastic
3
Neoplasms
3
Glioma
3
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Skin Neoplasms
1
Sexual Dysfunction, Physiological
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Recurrence
1
Rare Malignant Neoplasm
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Locally Advanced Thyroid Gland Carcinoma
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioblastoma
1
Ganglioneuroma
1
Ganglioglioma
1
Eunuchism
1
Interventions
Magnetic Resonance Spectroscopy
23
Radiosurgery
21
Temozolomide
14
Bevacizumab
11
pembrolizumab
10
Specimen Handling
9
Nivolumab
8
Radiotherapy
7
Ipilimumab
7
Magnetic Resonance Imaging
6
Cyclophosphamide
5
Capecitabine
5
Blood Specimen Collection
5
encorafenib
4
Radiation
4
Neuropsychological Tests
4
Mental Status and Dementia Tests
4
Memantine
4
Carboplatin
4
fludarabine
3
fluciclovine F-18
3
binimetinib
3
abemaciclib
3
Watchful Waiting
3
Proton Therapy
3
Etoposide
3
Dexamethasone
3
Adrenal Cortex Hormones
3
trastuzumab deruxtecan
2
sacituzumab govitecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Brain Neoplasms
×
dabrafenib
×
Clear all
NCT03563729
2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2
Recruiting
80 enrolled